Skip to content
Triangle logo TriangleGet started
← Full study record

NCT01459653 · OUTCOME

EP2006 Cycles by Treatment Duration

Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor · Source last updated 2016-01-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
cycles
Interval / dispersion
Not reported
Time frame
All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days

What was measured

Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery

Analysis population: All cycles from patients in the evaluable sample with study drug duration

Groups in this outcome

EP2006

Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
EP20061447

Analysis denominator · cycles

GroupSource count
EP20065942

Reported measurements

1 day
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006211Not reportedNot reportedNot reportedNot reported
2 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006339Not reportedNot reportedNot reportedNot reported
3 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006729Not reportedNot reportedNot reportedNot reported
4 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006422Not reportedNot reportedNot reportedNot reported
5 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP20062718Not reportedNot reportedNot reportedNot reported
6 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006385Not reportedNot reportedNot reportedNot reported
7 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006682Not reportedNot reportedNot reportedNot reported
8 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006115Not reportedNot reportedNot reportedNot reported
9 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP200653Not reportedNot reportedNot reportedNot reported
10 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006120Not reportedNot reportedNot reportedNot reported
11 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP200613Not reportedNot reportedNot reportedNot reported
12 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP200620Not reportedNot reportedNot reportedNot reported
13 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP20068Not reportedNot reportedNot reportedNot reported
14 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP2006105Not reportedNot reportedNot reportedNot reported
>=15 days
Values in cycles · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
EP200622Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        211
    title
    1 day
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        339
    title
    2 days
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        729
    title
    3 days
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        422
    title
    4 days
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        2718
    title
    5 days
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        385
    title
    6 days
  7. categories
    1. measurements
      1. group Id
        OG000
        value
        682
    title
    7 days
  8. categories
    1. measurements
      1. group Id
        OG000
        value
        115
    title
    8 days
  9. categories
    1. measurements
      1. group Id
        OG000
        value
        53
    title
    9 days
  10. categories
    1. measurements
      1. group Id
        OG000
        value
        120
    title
    10 days
  11. categories
    1. measurements
      1. group Id
        OG000
        value
        13
    title
    11 days
  12. categories
    1. measurements
      1. group Id
        OG000
        value
        20
    title
    12 days
denom Units Selected
Participants
denoms
  1. counts
    1. group Id
      OG000
      value
      1447
    units
    Participants
  2. counts
    1. group Id
      OG000
      value
      5942
    units
    cycles
description
Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery
groups
  1. description
    Cancer patients treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.
    id
    OG000
    title
    EP2006
param Type
NUMBER
population Description
All cycles from patients in the evaluable sample with study drug duration
reporting Status
POSTED
time Frame
All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days
title
EP2006 Cycles by Treatment Duration
type
PRIMARY
type Units Analyzed
cycles
unit Of Measure
cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice